Copertina

Technology‐based instrumental activities of daily living in persons with Alzheimer's disease and related disorders

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Jared F. Benge, Arsh Ali, Neha Chandna, Noor Rana, Rachel Mis, David A. González, Andrew M. Kiselica, Michael K. Scullin, Robin C. Hilsabeck
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Objective measures of instrumental activities of daily living and neuropsychiatric symptoms in aging and early‐stage Alzheimer's disease
di: Gad A. Marshall, et al.
Pubblicazione: (2025)

Treating Alzheimer's disease in a person living with HIV
di: David B. Clifford, et al.
Pubblicazione: (2026)

Prodromal Alzheimer's disease can affect activities of daily living for adults with Down syndrome
di: Tracy A. Listwan, et al.
Pubblicazione: (2024)

Bayesian analyses for research on Alzheimer's disease and related disorders—updating one's knowledge
di: Stefan Teipel, et al.
Pubblicazione: (2025)

Association between BrainAGE and Alzheimer's disease biomarkers
di: Yousaf Abughofah, et al.
Pubblicazione: (2025)

Longitudinal changes in the brain‐age gap in mild cognitive impairment and their relationships with neuropsychological functions and Alzheimer's disease biomarkers
di: Rachel R. Jin, et al.
Pubblicazione: (2025)

The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome
di: Julianne G. Clina, et al.
Pubblicazione: (2026)

Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?
di: María A. Rodríguez‐Santiago, et al.
Pubblicazione: (2024)

General practitioners’ perspectives on blood biomarkers for Alzheimer's disease
di: Thomas Claessen, et al.
Pubblicazione: (2025)

Atrophy signature for alpha‐synuclein copathology in Alzheimer's disease
di: Diana Esteller‐Gauxax, et al.
Pubblicazione: (2026)

Interchangeability of CSF and PET to identify Alzheimer's disease pathology
di: Samantha C. Burnham, et al.
Pubblicazione: (2026)

Diagnostic performance of light reflex pupillometry in Alzheimer's disease
di: Mathias Holsey Gramkow, et al.
Pubblicazione: (2024)

Cerebrospinal fluid sclerostin levels in the early Alzheimer's disease stages
di: Manuela Dicarlo, et al.
Pubblicazione: (2026)

Cerebrospinal fluid soluble insulin receptor levels in Alzheimer's disease
di: Peter Thomas, et al.
Pubblicazione: (2024)

Alzheimer's disease neuropathology and longitudinal change in subjective cognitive complaints
di: Alisa Bannerjee, et al.
Pubblicazione: (2025)

Longitudinal changes in functional capacity in frontotemporal dementia and Alzheimer's disease
di: David Foxe, et al.
Pubblicazione: (2024)

Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease
di: Sofia Toniolo, et al.
Pubblicazione: (2024)

Disentangling the genetic underpinnings of neuropsychiatric symptoms in Alzheimer's disease in the Alzheimer's Disease Sequencing Project: Study design and methodology
di: Nicholas R. Ray, et al.
Pubblicazione: (2024)

Caregivers’ attitudes toward blood‐based biomarker testing for Alzheimer's disease
di: Katharina Bolsewig, et al.
Pubblicazione: (2024)

Poor dream recall associates with Alzheimer's disease biomarkers and dementia risk
di: Darren M. Lipnicki, et al.
Pubblicazione: (2026)

Real‐world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West
di: Bethany C. Curd, et al.
Pubblicazione: (2026)

Amyloid accumulation, brain atrophy, and cognitive decline in emergent Alzheimer's disease
di: Ying Xia, et al.
Pubblicazione: (2025)

Machine learning models of Alzheimer's disease spectrum using blood tests
di: Nicola Walter Falasca, et al.
Pubblicazione: (2025)

Sensory changes in preclinical, prodromal, and clinical Alzheimer's disease and related dementias
di: Willa D. Brenowitz, et al.
Pubblicazione: (2026)

Effects of obesity on plasma biomarker and amyloid PET trajectories in Alzheimer's disease
di: Soheil Mohammadi, et al.
Pubblicazione: (2025)

White matter hyperintensities in Alzheimer's disease in the era of anti‐amyloid therapies
di: Antoine Garnier‐Crussard, et al.
Pubblicazione: (2026)

Serum biomarkers as prognostic markers for Alzheimer's disease in a clinical setting
di: Steffi De Meyer, et al.
Pubblicazione: (2025)

Peripheral oxidative stress related biomarkers in Alzheimer's disease: A systematic review of their implications for diagnosis and disease monitoring
di: George Nkrumah Osei, et al.
Pubblicazione: (2026)

Assessing Alzheimer's disease via plasma extracellular vesicle–derived mRNA
di: Le Hoang Phu Pham, et al.
Pubblicazione: (2024)

Brain‐derived tau to measure treatment effect in Alzheimer's disease and frontotemporal dementia
di: Cassandra Marotta, et al.
Pubblicazione: (2025)

Multilevel prediction of Alzheimer's disease dementia in the United States: An artificial intelligence analysis
di: Nicolaas P. Pronk, et al.
Pubblicazione: (2026)

Elevated tau in the piriform cortex in Alzheimer's but not Parkinson's disease using PET‐MR
di: Hossein Moein Taghavi, et al.
Pubblicazione: (2024)

Cognitive and functional performance and plasma biomarkers of early Alzheimer's disease in Down syndrome
di: Emily K. Schworer, et al.
Pubblicazione: (2024)

Divergent effects of age on imaging‐based ATN biomarkers and cognition in Alzheimer's disease
di: Lars Frings, et al.
Pubblicazione: (2025)

Plasma lipid metabolites as biomarkers of early white matter degeneration in Alzheimer's disease
di: Alireza Shaabanpoor Haghighi, et al.
Pubblicazione: (2025)

Identifying cognitive test scores associated with early tau burden in Alzheimer's disease
di: Caitlin M. Terao, et al.
Pubblicazione: (2025)

Web‐based LAS‐FNAME and blood biomarkers in autosomal dominant Alzheimer's disease
di: Christopher Gonzalez Corona, et al.
Pubblicazione: (2026)

Validation of regression‐based change formulae for mild cognitive impairment and Alzheimer's disease
di: Kevin Duff, et al.
Pubblicazione: (2024)

Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology
di: Lara Blömeke, et al.
Pubblicazione: (2024)

Tracking clinical and neuroimaging progression of Alzheimer's disease by longitudinal trajectories of plasma biomarkers
di: Frederikke Kragh Clemmensen, et al.
Pubblicazione: (2026)